Patents by Inventor Ronald Kotitschke

Ronald Kotitschke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5099003
    Abstract: A method of preparing a sterile and stable plasma-protein solution containing fibrinogen and Factor XIII from human blood plasma which has been stabilized with citrate, comprising treating the plasma with .beta.-propiolactone and irradiating it with ultraviolet light, removing the Factors II, VII, IX and X by adsorption onto anion exchangers that adsorb proteins, precipitating the companion proteins out by adding ethanol until the solution has a final concentration of about 9% by volume at -3.degree. C., centrifuging the precipitate off, dissolving the precipitate in a citrate buffer at a pH of about 6.35 and a temperature of about 37.degree. C., adjusting the protein level of the solution to about 13.3 g/l with sodium citrate solution, adding ethanol, a glycine citrate buffer, and a solution of sodium citrate to precipitate out the companion proteins, adding ethanol to the remaining solution until the solution has a final concentration of about 9% by volume at -3.degree. C.
    Type: Grant
    Filed: October 12, 1988
    Date of Patent: March 24, 1992
    Assignee: Biotest Pharma GmbH
    Inventors: Ronald Kotitschke, Axel W. Stemberger, Wolfgang Stephan
  • Patent number: 5075425
    Abstract: Process for the preparation of an immunoglobulin solution suitable for intravenous administration from a human blood protein fraction containing immunoglobulins IgG, IgA and IgM in partially concentrated from, with the process steps: addition of acetate buffer to the protein fraction, where appropriate removal of insoluble constituents by filtration, treatment with calcium phosphate and octanoic acid, centrifugation, removal of the supernatant and treatment thereof with an adsorbent, removal of the adsorbent and sterilization by filtration.
    Type: Grant
    Filed: August 1, 1990
    Date of Patent: December 24, 1991
    Assignee: Biotest Pharma GmbH
    Inventors: Ronald Kotitschke, Wolfgang Stephan, Wolfgang Moller, Detlef Piechaczek, Dieter Rudnick
  • Patent number: 4900720
    Abstract: To maintain an almost unchanged plasma-protein profile in a patient subsequent to plasma exchange, the plasma-exchange medium contains the most essential human serum proteins, except for the coagulation factors, at a concentration of 75 g/l.
    Type: Grant
    Filed: April 6, 1987
    Date of Patent: February 13, 1990
    Assignee: Boitest Pharma GmbH
    Inventor: Ronald Kotitschke
  • Patent number: 4503039
    Abstract: A coagulant plasma-protein solution obtained by adsorbing stabilized human plasma at least once with 20-40 mg of colloidal silicic acid per gram of plasma protein and separating the adsorbent from the adsorbate, a method of manufacturing the solution, and a pharmaceutical preparation containing the solution and intended for the intravenous treatment of complex disorders of the hemostatic system. The solution is low in fibrinogen and factors XI and XII but otherwise close in composition to the starting material.
    Type: Grant
    Filed: December 14, 1983
    Date of Patent: March 5, 1985
    Assignee: Biotest-Serum-Institut GmbH
    Inventors: Ronald Kotitschke, Wolfgang Stephan
  • Patent number: 4370264
    Abstract: A process for the cold sterilization of a preparation containing blood coagulation factor VIII, comprising(A) contacting a protein solution containing factor VIII with a physiologically compatible, non-ionogenic tenside, and then subjecting the solution to(B) irradiation with ultraviolet light,(C) treatment with beta-propiolactione, and(D) to an adsorption treatment with colloidal silica, steps B-C-D being performed in the sequence B-C-D, B-D-C, D-C-B or D-B-C.
    Type: Grant
    Filed: September 8, 1981
    Date of Patent: January 25, 1983
    Assignee: Biotest-Serum-Institut GmbH
    Inventors: Ronald Kotitschke, Wolfgang Stephan
  • Patent number: 4272523
    Abstract: The present invention relates to a method for making fibrinogen, a prothrombin complex containing the coagulation factors II, VII, IX and X that can contain antithrombin III, antithrombin III and a solution of stable serum proteins from a blood plasma stabilized with citrate which is characterized in that from the plasma, by adsorption on colloidal silica of a specific surface of 50 to 400 m.sup.
    Type: Grant
    Filed: September 17, 1979
    Date of Patent: June 9, 1981
    Assignee: Biotest Serum Institut GmbH
    Inventors: Ronald Kotitschke, Wolfgang Stephan
  • Patent number: 4170590
    Abstract: A citrate-stabilized blood plasma is frozen and thawed, the undissolved cryoprecipitate is separated and is rich in factor VIII protein. The residual liquid is treated with cation and anion exchangers, either sequentially or in admixture, to separate calcium and citrate ions therefrom. The residual plasma is then subjected to adsorption to remove a fraction which is eluted and precipitated, enriched in factors II, VII, IX and X. The liquid left from adsorption is subjected to further adsorption with silicic acid, leaving a storage-stable serum. The silicic acid is eluted to dissolve adsorbed fibrinogen which then is re-precipitated.
    Type: Grant
    Filed: February 6, 1978
    Date of Patent: October 9, 1979
    Assignee: Biotest-Serum-Institut GmbH
    Inventors: Wolfgang Stephan, Ronald Kotitschke
  • Patent number: 4147765
    Abstract: An antiserum for the quantitative determination of X and Y degradation products of fibrin and fibrinogen is produced by administering the purified degradation products to an experimental animal thereby to immunize said animal, drawing serum from said animal, contacting said serum with a plasma and separating the resultant precipitate, thereby to leave a supernatant liquid which constitutes said antiserum. The plasma may be a heparin, citrate, oxalate, ethylenediaminetetracetate or glutaraldehyde-treated plasma and as many as 12 or 15 precipitations may be made with the animal antiserum. The antiserum may be fractionated at any stage by adsorption on Sephadex modified dextran.
    Type: Grant
    Filed: July 16, 1976
    Date of Patent: April 3, 1979
    Assignee: Biotest-Serum-Institut GmbH
    Inventors: Wolfgang Stephan, Ronald Kotitschke
  • Patent number: 4081431
    Abstract: A process for the fractionation of blood comprising passing said blood through a cation exchanger, separating the solids from the plasma, freezing the plasma, thawing the frozen plasma, and separating a first product comprising undissolved cryoprecipitate enriched in factor-VIII protein from plasma fluid. The cryoprecipitate can be concentrated by warm water dissolution and polyethylene glycol precipitation. The plasma fluid, optionally after treatment with .beta.-propiolactone and uv irridiation, is treated with tricalcium phosphate to adsorb factors II, VII, IX and X as a second product. These factors can be eluted with citrate solution. The residual plasma from the initial tricalcium phosphate adsorption is treated with colloidal silica to adsorb impurities and leave a third product which is a storage-stable serum protein solution.
    Type: Grant
    Filed: December 11, 1975
    Date of Patent: March 28, 1978
    Assignee: Biotest-Serum-Institut GmbH
    Inventors: Wolfgang Stephan, Ronald Kotitschke